Request for Covid-19 Impact Assessment of this Report

Medical Devices

Global Iodinated Contrast Media in Interventional X-Ray Market - Industry Trends and Forecast To 2027

  • DAT3384304
  • 243 Pages
  • November 2019
  • Medical Devices
Download Sample    Get Discount   
 
Global iodinated contrast media in interventional X-ray market is projected to register a substantial CAGR of 5.3 % in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

By Route of Administration (Intravenous, Oral, Rectal, Others), Indication (Cardiology, Neurology, General Surgery, Oncology, Urology), Agent Type (Non-Ionic, Ionic), End User (Hospital, Specialty Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research & Academic Institutes), Country ( U.S., Canada, Mexico,, Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Russia, Belgium, Turkey, Rest Of Europe, China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, UAE, Saudi Arabia, Egypt, South Africa, Israel, Rest of Middle East and Africa) Market Trends and Forecast to 2027

Some of the major factors contributing to the growth of the market are:

• Increasing health care expenditure

• Increasing genetic population

Market Players:

The key market players for global iodinated contrast media in interventional X-ray market are listed below:

• Bayer AG

• Iso-Tex Diagnostics, Inc.

• Bracco Diagnostic Inc.

• Novalek Pharmaceuticals Pvt. Ltd.

• iMAX

• Taejoon Pharm

• Unijules Life Sciences Ltd

• General Electric

• Guerbet LLC

• J.B.Chemicals & Pharmaceuticals Ltd

TABLE OF CONTENTS

1 INTRODUCTION 28

1.1 OBJECTIVES OF THE STUDY 28

1.2 MARKET DEFINITION 28

1.3 OVERVIEW OF GLOBAL IODINATED CONTRAST MEDIA IN INTERVENTIONAL X-RAY MARKET 28

1.4 LIMITATIONS 29

1.5 MARKETS COVERED 29

2 MARKET SEGMENTATION 32

2.1 MARKETS COVERED 32

2.2 GEOGRAPHICAL SCOPE 33

2.3 YEARS CONSIDERED FOR THE STUDY 34

2.4 CURRENCY AND PRICING 34

2.5 DBMR TRIPOD DATA VALIDATION MODEL 35

2.6 MULTIVARIATE MODELLING 38

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 39

2.8 APPLICATION GRID 40

2.9 DBMR MARKET POSITION GRID 41

2.10 VENDOR SHARE ANALYSIS 42

2.11 SECONDARY SOURCES 43

2.12 ASSUMPTION 43

3 MARKET OVERVIEW 44

3.1 DRIVERS 46

3.1.1 LARGE NUMBER OF APPROVALS FOR IODINATED AGENTS 46

3.1.2 RISING AGING POPULATION 47

3.1.3 INCREASING NUMBER OF CHRONIC DISEASES 50

3.1.4 INCREASING RESEARCH ACTIVITIES FOR CONTRAST AGENTS 51

3.2 RESTRAINTS 52

3.2.1 HIGH COST OF CONTRAST MEDIA 52

3.2.2 SIDE EFFECTS ASSOCIATED WITH CONTRAST AGENTS 52

3.3 OPPORTUNITIES 53

3.3.1 GROWING HEALTHCARE INFRASTRUCTURE 53

3.3.2 STRATEGIC INITIATIVE BY MARKET PLAYERS 54

3.3.3 GROWING NUMBER OF DIAGNOSTIC CENTERS 54

3.3.4 UPCOMING GENERIC CONTRAST MEDIA AGENTS 55

3.4 CHALLENGES 56

3.4.1 LACK OF AWARENESS REGARDING THE PROPER DOSAGE OF CONTRAST AGENT 56

3.4.2 RESTRICTION AND WITHDRAWAL OF LINEAR GADOLINIUM-BASED CONTRAST AGENTS 57

4 EXECUTIVE SUMMARY 58

5 PREMIUM INSIGHTS 61

6 GLOBAL IODINATED CONTRAST MEDIA IN INTERVENTIONAL X-RAY MARKET, BY ROUTE OF ADMINISTRATION 64

6.1 OVERVIEW 65

6.2 INTRAVENOUS 67

6.3 ORAL 68

6.4 RECTAL 68

6.5 OTHERS 69

7 GLOBAL IODINATED CONTRAST MEDIA IN INTERVENTIONAL X-RAY MARKET, BY END USER 70

7.1 OVERVIEW 71

7.2 HOSPITAL 74

7.3 SPECIALTY CLINICS 74

7.3.1 IMAGING CENTERS 75

7.3.2 PRIVATE PRACTICES 75

7.4 DIAGNOSTIC CENTERS 75

7.5 AMBULATORY SURGICAL CENTERS 75

7.6 RESEARCH & ACADEMIC INSTITUTES 76

8 GLOBAL IODINATED CONTRAST MEDIA IN INTERVENTIONAL X-RAY MARKET, BY INDICATION 77

8.1 OVERVIEW 78

8.2 CARDIOLOGY 80

8.2.1 PERCUTANEOUS CORONARY DISEASE 81

8.2.2 STRUCTURAL HEART DISEASE 81

8.2.3 CONGENITAL HEART DISEASE 81

8.2.4 ELECTROPHYSIOLOGY 81

8.3 NEUROLOGY 81

8.4 GENERAL SURGERY 82

8.5 ONCOLOGY 82

8.6 UROLOGY 83

9 GLOBAL IODINATED CONTRAST MEDIA IN INTERVENTIONAL X-RAY MARKET, BY AGENT TYPE 84

9.1 OVERVIEW 85

9.2 NON-IONIC 87

9.3 IONIC 88

10 GLOBAL IODINATED CONTRAST MEDIA IN INTERVENTIONAL X-RAY MARKET, BY GEOGRAPHY 89

10.1 OVERVIEW 90

10.2 NORTH AMERICA 95

10.2.1 U.S. 101

10.2.2 CANADA 104

10.2.3 MEXICO 107

10.3 EUROPE 110

10.3.1 GERMANY 116

10.3.2 U.K. 119

10.3.3 FRANCE 122

10.3.4 ITALY 125

10.3.5 SPAIN 128

10.3.6 SWITZERLAND 131

10.3.7 NETHERLANDS 134

10.3.8 RUSSIA 137

10.3.9 BELGIUM 140

10.3.10 TURKEY 143

10.3.11 REST OF EUROPE 146

10.4 ASIA-PACIFIC 147

10.4.1 CHINA 153

10.4.2 JAPAN 156

10.4.3 SOUTH KOREA 159

10.4.4 INDIA 161

10.4.5 AUSTRALIA 164

10.4.6 SINGAPORE 167

10.4.7 THAILAND 170

10.4.8 MALAYSIA 173

10.4.9 INDONESIA 176

10.4.10 PHILIPPINES 179

10.4.11 REST OF ASIA-PACIFIC 182

10.5 SOUTH AMERICA 183

10.5.1 BRAZIL 189

10.5.2 ARGENTINA 192

10.5.3 PERU 195

10.5.4 REST OF SOUTH AMERICA 198

10.6 MIDDLE EAST AND AFRICA 199

10.6.1 U.A.E. 205

10.6.2 SAUDI ARABIA 208

10.6.3 EGYPT 211

10.6.4 SOUTH AFRICA 214

10.6.5 ISRAEL 217

10.6.6 REST OF MIDDLE EAST & AFRICA 220

11 GLOBAL IODINATED CONTRAST MEDIA IN INTERVENTIONAL X-RAY MARKET, COMPANY LANDSCAPE 221

11.1 COMPANY SHARE ANALYSIS: GLOBAL 221

11.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 222

11.3 COMPANY SHARE ANALYSIS: EUROPE 223

11.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 224

12 COMPANY PROFILES 225

12.1 BRACCO DIAGNOSTIC INC. 225

12.1.1 COMPANY SNAPSHOT 225

12.1.2 COMPANY SHARE ANALYSIS 225

12.1.3 PRODUCT PORTFOLIO 225

12.1.4 RECENT DEVELOPMENT 226

12.2 GENERAL ELECTRIC 227

12.2.1 COMPANY SNAPSHOT 227

12.2.2 REVENUE ANALYSIS 228

12.2.3 COMPANY SHARE ANALYSIS 228

12.2.4 PRODUCT PORTFOLIO 229

12.2.5 RECENT DEVELOPMENTS 229

12.3 GUERBET 230

12.3.1 COMPANY SNAPSHOT 230

12.3.2 REVENUE ANALYSIS 230

12.3.3 COMPANY SHARE ANALYSIS 231

12.3.4 PRODUCT PORTFOLIO 231

12.3.5 RECENT DEVELOPMENT 231

12.4 BAYER AG 232

12.4.1 COMPANY SNAPSHOT 232

12.4.2 REVENUE ANALYSIS 232

12.4.3 PRODUCT PORTFOLIO 233

12.4.4 RECENT DEVELOPMENT 233

12.5 IMAX 234

12.5.1 COMPANY SNAPSHOT 234

12.5.2 PRODUCT PORTFOLIO 234

12.5.3 RECENT DEVELOPMENT 234

12.6 ISO-TEX DIAGNOSTICS, INC. 235

12.6.1 COMPANY SNAPSHOT 235

12.6.2 PRODUCT PORTFOLIO 235

12.6.3 RECENT DEVELOPMENT 235

12.7 J.B.CHEMICALS AND PHARMACEUTICALS LTD. 236

12.7.1 COMPANY SNAPSHOT 236

12.7.2 REVENUE ANALYSIS 236

12.7.3 PRODUCT PORTFOLIO 237

12.7.4 RECENT DEVELOPMENT 237

12.8 NOVALEK PHARMACEUTICALS PVT. LTD. 238

12.8.1 COMPANY SNAPSHOT 238

12.8.2 PRODUCT PORTFOLIO 238

12.8.3 RECENT DEVELOPMENT 238

12.9 TAEJOON PHARM 239

12.9.1 COMPANY SNAPSHOT 239

12.9.2 PRODUCT PORTFOLIO 239

12.9.3 RECENT DEVELOPMENT 239

12.10 UNIJULES LIFE SCIENCES LTD. 240

12.10.1 COMPANY SNAPSHOT 240

12.10.2 PRODUCT PORTFOLIO 240

12.10.3 RECENT DEVELOPMENT 240

13 QUESTIONNAIRE 241

14 RELATED REPORTS 243

 
Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Contact Us

+ 1-888-961-4454

Drop Us an email at

help@bigmarketresearch.com

Similar Reports

Medical Implants Market By Type (Orthopedic Implants, cardiac implants, Stents, Spinal Implants, Neurostimulators, dental implants, Breast Implants, facial Implants) and By Materials (Metallic, Ceramic, Polymers, Natural) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022

Medical implants are permanent devices such as pacemakers or temporary devices such as fracture plates which are removed once their function is completed. These implants are made up of bone, tissue, skin, ceramics, metals, plastics, and other natural materials...

  • Publish Date: August 21, 2016
  • $5370
Ostomy Drainage Bags Market by Type (Colostomy Bags, Ileostomy Bags, Urostomy Bags, Continent Urostomy Bags, and Continent Ileostomy Bags) - Global Opportunity Analysis and Industry Forecast, 2014-2022

Ostomy is a surgery wherein an artificial opening, known as stoma, is created from the colon in the human body to eliminate body wastes such as urine, mucus, and stools, which are collected in artificial bags called ostomy drainage bags. These plastic/rub...

  • Publish Date: December 1, 2016
  • $5370